<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091272</url>
  </required_header>
  <id_info>
    <org_study_id>B1661001</org_study_id>
    <nct_id>NCT01091272</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04995274 After Administration Of Single Oral Doses To Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of PF-04995274 after
      administration of a single dose to healthy volunteers, and to evaluate the plasma drug
      concentrations after single dose in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is to evaluate the safety and pharmacokinetics of a single dose of PF-04995274 in
      healthy adult volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoints (AE's, Vital signs (supine &amp; standing BP, PR), Triplicate ECG, 8 hours of cardiac telemetry postdose, Clinical safety laboratory endpoints, Digit Symbol Substitution Test (DSST), Drug Effect Questionnaire (DEQ), Clinical</measure>
    <time_frame>up to 21 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>examinations)</measure>
    <time_frame>up to 21 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, Tmax, AUClast, AUCinf, and t1/2 of PF 04995274, as the data permit.</measure>
    <time_frame>up to 7 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, Tmax, AUClast, AUCinf, and t1/2 of PF 05082547, as the data permit.</measure>
    <time_frame>up to 7 days post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone concentrations</measure>
    <time_frame>through 1 day post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 3 period interleaved cross-over with placebo substitution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 4 period interleaved cross-over, placebo substitution, with food effect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 4 period cross-over, placebo insertion, with food effect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 3 period cross-over with placebo substitution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04995274</intervention_name>
    <description>Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04995274</intervention_name>
    <description>Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04995274</intervention_name>
    <description>Planned single PO 120mg and 210mg doses of PF-04995274</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04995274</intervention_name>
    <description>single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data</description>
    <arm_group_label>Optional Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For all cohorts, healthy male and/or female subjects of nonchildbearing potential
             between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically
             relevant abnormalities identified by a detailed medical history, full physical
             examination, including blood pressure and heart rate measurement, 12 lead ECG and
             clinical laboratory tests).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Pregnant or nursing women; women of childbearing potential. Female subjects must be of
             non childbearing potential defined by a history of surgical sterilization (eg,
             hysterectomy or bilateral oophorectomy) or post menopausal status (complete absence of
             menses for at least two consecutive years) and elevated FSH concentration in women
             between 45 and 55.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1661001&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%20And%20Plasma%20Drug%20Levels%20Following%20A%20Single%20Dose%20Of%20PF-04995274%20In%20Healthy%20Adult%20Voluntee</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>September 17, 2010</last_update_submitted>
  <last_update_submitted_qc>September 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>healthy volunteer</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

